AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT05719506
Drug: Dexmedetomidine
RxNorm normalized name: Dexmedetomidine
DrugBank: Dexmedetomidine (DB00633)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: nebulizer session with dexmedetomidine preoperative
Trial: NCT05719506
Drug: Ketamine
RxNorm normalized name: Ketamine
DrugBank: Ketamine (DB01221)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: nebulizer session with ketamine preoperative
Trial: NCT04877275
Drug: Selinexor (80mg/d)
RxNorm normalized name: selinexor
DrugBank: Selinexor (DB11942)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Selinexor (ATG-010） is a first-in-class, oral selective exportin 1 (XPO1) inhibitor (1,2). Selinexor functions by binding with and inhibiting the nuclear export protein XPO1 (also called CRM1), leading to the accumulation of tumor suppressor proteins in the cell nucleus along with inhibition of translation of oncoprotein mRNAs.~Arm I：80mg/d QW ;
Trial: NCT04877275
Drug: Selinexor (100mg/d)
DrugBank: Selinexor (DB11942)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Selinexor (ATG-010） is a first-in-class, oral selective exportin 1 (XPO1) inhibitor (1,2). Selinexor functions by binding with and inhibiting the nuclear export protein XPO1 (also called CRM1), leading to the accumulation of tumor suppressor proteins in the cell nucleus along with inhibition of translation of oncoprotein mRNAs.~Arm II：100mg/d QW ;
Trial: NCT06490068
Drug: LTC004+Toripalimab
RxNorm normalized name: Toripalimab
DrugBank: Toripalimab (DB15043)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LTC004 on D1 of Week 1 and D1 of week 3. IV,90μg/kg. Beginning at week 5, all subjects will receive LTC004 in combination with Toripalimab.~LTC004:D3,iv,45μg/kg,Q3W. Toripalimab:D1,iv,240mg,Q3W.
Trial: NCT04877275
Drug: Dexamethasone
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Dexamethasone 40mg/d QW
Trial: NCT04930549
Drug: Dapagliflozin 10Mg Tab
RxNorm normalized name: DAPAGLIFLOZIN 10MG TAB
DrugBank: Dapagliflozin (DB06292)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Patients receive dapagliflozin 10mg tablets once a day during 12 weeks
Trial: NCT04407650
Drug: Metformin
RxNorm normalized name: Metformin
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Patients will be randomized to each intervention using minimisation:~* BMI category (Overweight/Obese),~* Previous history of GDM,~* Disease severity (baseline fasting glucose ≤6.2 or \>6.2),~* Recruitment centre
Trial: NCT04407650
Drug: Ursodeoxycholic Acid
RxNorm normalized name: Ursodeoxycholic acid
DrugBank: Ursodeoxycholic acid (DB01586)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will be randomized to each intervention using minimisation:~* BMI category (Overweight/Obese),~* Previous history of GDM,~* Disease severity (baseline fasting glucose ≤6.2 or \>6.2),~* Recruitment centre
Trial: NCT04903873
Drug: EU101
RxNorm normalized name: Etanercept
DrugBank: Etanercept (DB00005)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: EU101 will be administered via intravenous infusion.
Trial: NCT05926349
Drug: Andexanet alfa
RxNorm normalized name: andexanet alfa
DrugBank: Andexanet alfa (DB14562)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Andexanet is a recombinant version of human FXa
Trial: NCT04869579
Drug: Selenium (as Selenious Acid)
RxNorm normalized name: selenium (as selenious acid)
DrugBank: Selenium (DB11135)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Interventional arm participants will receive Selenium as Selenious Acid infusion plus the standard of care therapy.
Trial: NCT01825395
Drug: 3, 4-Diaminopyridine
DrugBank: Amifampridine (DB11640)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT04811443
Drug: Empegfilgrastim
RxNorm normalized name: Empegfilgrastim
DrugBank: Empegfilgrastim (DB16155)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Extimia®
Trial: NCT05634746
Drug: APT-1011
RxNorm normalized name: tetracycline
DrugBank: APT-101 (DB18003)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: APT-1011 is an orally disintegrating tablet that includes fluticasone propionate as its active ingredient.~Other Names:~fluticasone propionate
Trial: NCT05082051
Drug: Part A
RxNorm normalized name: diluent for insulin aspart and detemir no.1
DrugBank: Insulin aspart (DB01306)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Randomized, double-blind, placebo-controlled dose escalation part to investigate the safety, tolerability, immunogenicity, and PK of CDX-7108 after single oral dose administration in healthy adult subjects.~Single-dose administration of CDX-7108 at the following anticipated dose levels. 10 000, 50 000, 150 000, 250 000, and 500 000 lipase units will be evaluated in 5 sequential cohorts of 6 subjects each.
Trial: NCT05082051
Drug: Part C
RxNorm normalized name: diluent,insulin aspart combination no.1 INJECTION VIAL (ML)
DrugBank: Insulin aspart (DB01306)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Randomized, double-blind, placebo-controlled, single-dose, 2-way crossover part to assess POC of CDX-7108 in terms of PD as well as its safety, tolerability, and immunogenicity in subjects with EPI.~Approximately 10 subjects with severe EPI from partial/total pancreatectomy or chronic pancreatitis will be enrolled. It is anticipated that Part C (POC study) will commence after completion of the third single-dose cohort from Part A (SAD study) and following SRC review of the data from this cohort.
Trial: NCT04906720
Drug: Colchicine
RxNorm normalized name: Colchicine
DrugBank: Colchicine (DB01394)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: colchicine 0.6mg oral twice daily for 7 days
Trial: NCT06595823
Drug: Betadine
RxNorm normalized name: Betadine
DrugBank: Povidone-iodine (DB06812)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: To compare between Betadine (10%) and saline (0.9%) in swapping of subcutaneous tissue for prevention of surgical site infection after primary elective caesarian section.
Trial: NCT06607107
Drug: mFOLFOX7 combined with Camrelizumab and apatinib
RxNorm normalized name: miconazole
DrugBank: Camrelizumab (DB14776)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: mFOLFOX7(Oxaliplatin 85mg/m2, Calcium Levofolinate 200mg/m2, Fluorouracil 400 mg/m2 D1，2400mg/m2 maintain 46 hours，) combined with Apatinib and Camrelizumab 200mg every 3 weeks. Taking Apatinib-Mesylate Tablets (250 mg/tablet) orally after meals, once a day, for continuous medication.
Trial: NCT06606821
Drug: Tirzepatide
RxNorm normalized name: Tirzepatide
DrugBank: Tirzepatide (DB15171)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Investigational drug will be administered as a sc. injection once-weekly.
Trial: NCT04865731
Drug: Dermaprazole
RxNorm normalized name: miconazole nitrate / salicylic acid Medicated Shampoo [Dermazole]
DrugBank: Salicylic acid (DB00936)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will be managed with twice daily prophylactic use of the proposed intervention (Dermaprazole) topical cream for radiation dermatitis. The amount of cream will be 2cc per application and will be measured in pre-filled capped syringes for every application.
Trial: NCT04865731
Drug: Aquaphor
RxNorm normalized name: Aquaphor
DrugBank: Petrolatum (DB11058)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will be managed with twice daily prophylactic use of Aquaphor. The amount of Aquaphor will be 2cc per application and will be measured in pre-filled capped syringes for every application.
Trial: NCT06352892
Drug: Maridebart Cafraglutide
RxNorm normalized name: Maridebart Cafraglutide
DrugBank: Maridebart Cafraglutide (DB19339)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Solution for SC injection.
Trial: NCT05475665
Drug: Irbesartan/Amlodipine
DrugBank: Amlodipine (DB00381)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Irbesartan/Amlodipine once daily for 8 weeks
Trial: NCT05475665
Drug: Irbesartan
RxNorm normalized name: Irbesartan
DrugBank: Irbesartan (DB01029)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Irbesartan once daily for 8 weeks
Trial: NCT06379958
Drug: Itraconazole 200 mg
RxNorm normalized name: itraconazole 200 MG
DrugBank: Itraconazole (DB01167)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral capsule
Trial: NCT06379958
Drug: Upadacitinib 15 MG
RxNorm normalized name: upadacitinib 15 MG
DrugBank: Upadacitinib (DB15091)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Oral Capsule
Trial: NCT04703608
Drug: Ivermectin
RxNorm normalized name: Ivermectin
DrugBank: Ivermectin (DB00602)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ivermectin 0.3-0.4mg/Kg daily for 3 days.
Trial: NCT04703608
Drug: ASP
RxNorm normalized name: Asp
DrugBank: Aspartic acid (DB00128)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Aspirin 150mg daily for 28 days or until hospital discharge (whichever is sooner)
Trial: NCT05008575
Drug: Fludarabine
RxNorm normalized name: Fludarabine
DrugBank: Fludarabine (DB01073)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: recommendation: 30mg/m2 (D-5\~D-3),determined by tumor burden at baseline.
Trial: NCT05008575
Drug: Cytoxan
RxNorm normalized name: Cytoxan
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: recommendation: 300-500mg/m2 (D-5\~D-3),determined by tumor burden at baseline.
Trial: NCT05460273
Drug: Datopotamab Deruxtecan (Dato-DXd)
RxNorm normalized name: Datopotamab deruxtecan
DrugBank: Datopotamab deruxtecan (DB16410)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dato-DXd is an antibody-drug conjugate (ADC) that binds to TROP2.
Trial: NCT04911907
Drug: utidelone injection
RxNorm normalized name: Utidelone
DrugBank: Utidelone (DB17575)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Utidelone monotherapy 35 mg/m2/day IV transfusing over 90 min. on day 1-day 5 of each 21 day cycle
Trial: NCT05963087
Drug: Cetuximab Dabrafenib Tislelizumab
RxNorm normalized name: Tislelizumab
DrugBank: Cetuximab (DB00002)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Dabrafenib 150mg，BID, Cetuximab 250mg/m2, Tislelizumab 200mg Treatment every three weeks
Trial: NCT04752137
Drug: Indocyanine green
RxNorm normalized name: Indocyanine Green
DrugBank: Indocyanine green (DB16024)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: The SPY PHI and its dye Indocyanine Green dye (ICG) is a non-invasive device that is connected to a light source tower that is already available in the hospital in the operating room under Gynecology and Obstetrics Equipment. This is a special light source lamp that allows to test for vascularity in the soft tissues intraoperatively. Previous research in animal models proved the concept that the increased vascularity in tumors can be used to use this device to improve intraoperative assessment of tumor margins during resection. Our study will help to establish a correlation between activity with the dye and histological findings. This information has the potential to help sarcoma patients by avoiding staged surgeries, decreasing hospitalization times, and decreasing the likelihood of local recurrence by improving margin quality.
Trial: NCT04753658
Drug: lorlatinib
RxNorm normalized name: LORLATINIB
DrugBank: Lorlatinib (DB12130)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Oral
Trial: NCT05142254
Drug: Tadalafil
RxNorm normalized name: Tadalafil
DrugBank: Tadalafil (DB00820)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 2.5-5 mg/day
Trial: NCT05142254
Drug: Hydroxyurea
RxNorm normalized name: Hydroxyurea
DrugBank: Hydroxyurea (DB01005)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg/kg/day
Trial: NCT06017921
Drug: Eszopiclone 3 mg
RxNorm normalized name: eszopiclone 3 MG
DrugBank: Eszopiclone (DB00402)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients starting CPAP treatment will be randomized to either Eszopiclone or Placebo arm
Trial: NCT05223907
Drug: Etomidate
RxNorm normalized name: Etomidate
DrugBank: Etomidate (DB00292)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Etomidate will be used for general anesthesia
Trial: NCT05223907
Drug: Propofol
RxNorm normalized name: Propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Propofol will be used for general anesthesia
Trial: NCT06054217
Drug: Vehicle of TP-03
RxNorm normalized name: Oil of peppermint
DrugBank: Peppermint oil (DB11198)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The Exploratory Vehicle is the vehicle of TP-03 (lotilaner ophthalmic solution, 0.25%)
Trial: NCT00234481
Drug: XL844
RxNorm normalized name: XL844
DrugBank: XL844 (DB05149)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT05106712
Drug: Vitamin D3
RxNorm normalized name: Vitamin D3
DrugBank: Cholecalciferol (DB00169)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4000IU per day for around 12 weeks.
Trial: NCT05106712
Drug: Clomiphene Citrate
RxNorm normalized name: Clomiphene Citrate
DrugBank: Clomifene (DB00882)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: oral Clomiphene citrate using its respective Stair-step dosage protocol as follow: 50 mg, 100 mg, and 150 mg, once daily for 5 days, in the 1st, 2nd, and 3rd cycle, respectively.
Trial: NCT05106712
Drug: Letrozole
RxNorm normalized name: Letrozole
DrugBank: Letrozole (DB01006)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: oral Letrozole using its respective Stair-step dosage protocol as follow: 5 mg, 5 mg, and 7.5 mg, once daily for 5 days, in the 1st, 2nd, and 3rd cycle, respectively, respectively.
Trial: NCT05774054
Drug: Crystalloid
RxNorm normalized name: Crystal ammonia
DrugBank: Ammonium carbonate (DB15926)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: received (30ml /kg) ringer's lactate solution after first presentation then norepinephrine was added when persistent mean arterial pressure (MAP)\> 65 mmHg despite adequate fluid resuscitation
Trial: NCT05774054
Drug: noradrenaline
RxNorm normalized name: Noradrenaline
DrugBank: Norepinephrine (DB00368)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: received ( 30ml /kg) ringer's lactate solution after first presentation combined with norepinephrine infusion (0.05 mic/kg/min)
Trial: NCT06157996
Drug: lenvatinib and tislelizumab plus CapeOX chemotherapy
RxNorm normalized name: Tislelizumab
DrugBank: Lenvatinib (DB09078)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Tislelizumab 200mg, iv, d1+ oxaliplatin 130mg/m2, iv, d1+ capecitabine 1000mg/m2, bid po, D1-14, q3w + Lenvatinib 8mg, qd po regimen are received, respectively (3 weeks as a cycle, a maximum of 8 cycles of treatment). Then the maintenance treatment phase with tislelizumab + lenvatinib is entered, and the specific dosage is the same as the treatment period.
Trial: NCT06157996
Drug: tislelizumab plus CapeOX chemotherapy
RxNorm normalized name: Tislelizumab
DrugBank: Tislelizumab (DB14922)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tislelizumab 200mg, iv, d1+ oxaliplatin 130mg/m2, iv, d1+ capecitabine 1000mg/m2, bid po, D1-14, q3w regimen are received, respectively (3 weeks as a cycle, a maximum of 8 cycles of treatment). Then the maintenance treatment phase with tislelizumab is entered, and the specific dosage is the same as the treatment period.
Trial: NCT05308472
Drug: DISC-1459
RxNorm normalized name: xylitol
DrugBank: Xylitol (DB11195)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral dose level 1, once a day for 120 days
Trial: NCT05308472
Drug: DISC-1459
RxNorm normalized name: xylitol
DrugBank: Xylitol (DB11195)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral dose level 2, once a day for 120 days
Trial: NCT05308472
Drug: DISC-1459
RxNorm normalized name: xylitol
DrugBank: Xylitol (DB11195)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral dose level 1, once a day for up to 8 months
Trial: NCT04726332
Drug: XL102
RxNorm normalized name: Lacosamide
DrugBank: Lacosamide (DB06218)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: oral doses of XL102
Trial: NCT04958044
Drug: Calcium Gluconate
RxNorm normalized name: Calcium Gluconate
DrugBank: Calcium gluconate (DB11126)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Calcium electroporation
Trial: NCT05220280
Drug: Imatinib
RxNorm normalized name: Imatinib
DrugBank: Imatinib (DB00619)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Oral imatinib 400 mg tablet once a day for 14 days.
Trial: NCT05220280
Drug: Infliximab
RxNorm normalized name: Infliximab
DrugBank: Infliximab (DB00065)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Infliximab is administered as a single IV infusion with the proposed dosing schedule of 5 mg/kg body weight.
Trial: NCT05641428
Drug: Axi-cel
RxNorm normalized name: Obe-cel
DrugBank: Obecabtagene autoleucel (DB17362)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Infusion with a single target dose of 2.0 x 10\^6 Standard of Care CAR T-cells/kg BW (range 1 -2.0x 10\^6 CAR T-cells /kg BW).
Trial: NCT04773782
Drug: avapritinib
RxNorm normalized name: Avapritinib
DrugBank: Avapritinib (DB15233)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: oral administration
Trial: NCT05891886
Drug: Oxygen Therapy
DrugBank: Oxygen (DB09140)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Study subjects will be asked to breathe supplemental, or extra, oxygen during several time periods.
Trial: NCT04915989
Drug: GX-19N
RxNorm normalized name: zinc pyrithione
DrugBank: Pyrithione (DB06815)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DNA vaccine expressing SARS-CoV-2 S-protein antigen including the Nucleocapsid protein (NP) antigen
Trial: NCT04726332
Drug: Fulvestrant
RxNorm normalized name: Fulvestrant
DrugBank: Fulvestrant (DB00947)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: fulvestrant 500 mg administered as an intramuscular (IM) injection every 2 weeks for the first 3 doses and then every 4 weeks.
Trial: NCT04726332
Drug: Abiraterone
RxNorm normalized name: ABIRATERONE
DrugBank: Abiraterone (DB05812)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: abiraterone 1000 mg administered orally once daily.
Trial: NCT04726332
Drug: Prednisone
RxNorm normalized name: Prednisone
DrugBank: Prednisone (DB00635)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: prednisone 5 mg administered orally twice daily.
Trial: NCT04420572
Drug: ozone injection
RxNorm normalized name: ozone
DrugBank: Ozone (DB12510)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ozone injection will be applied in three doses (1st, 4th, 7th and 10th days) for a total of 4 doses. In ozone injection applications, 1st dose 25 gamma, 2nd dose 20 gamma, 3rd and 4th dose 15 gamma 10 cc ozone will be injected.
Trial: NCT04420572
Drug: betamethasone
RxNorm normalized name: Betamethasone
DrugBank: Betamethasone (DB00443)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1ml betamethasone will be used for steroid injection.
Trial: NCT06604819
Drug: Ozone gel placed after closed sinus lifting then implant placed simultaneously.
DrugBank: Ozone (DB12510)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The patient received closed sinus lifting using osteotomes then ozone gel is prepared. Pure olive oil was blasted with 25 μ/ml O3 gas for two days, or until the oil changed from a greenish-colored liquid to a whitish gel. The longevity Ext 120 ozone generator executed out this process then implants were placed.
Trial: NCT06605690
Drug: Dalpiciclib and Letrozole Combined With Anlotinib
RxNorm normalized name: Letrozole
DrugBank: Letrozole (DB01006)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dalpiciclib: 150mg orally, once daily, d1-d21, every 28 days as a cycle (3 weeks / 1 week off) Letrozole: 2.5mg orally once daily (continuous) Anlotinib: 12mg orally, once daily, d1-d14, every 21 days as a cycle (use 2 weeks/stop 1 week). One of the last cycles of the new auxiliary The combination of anlotinib is not included in the treatment regimen to ensure that the time interval between anlotinib withdrawal and surgery is more than 2-3 weeks.
Trial: NCT05694312
Drug: Ibrutinib 420 mg
RxNorm normalized name: ibrutinib 420 MG
DrugBank: Ibrutinib (DB09053)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Patients will receive ibrutinib orally on days 1-28. Treatment repeats every 28 days for up to 12 cycles in the absence of CLL progression or unacceptable toxicity.
Trial: NCT03564964
Drug: SUVN-502
RxNorm normalized name: SUVN-502
DrugBank: SUVN-502 (DB06140)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablet
Trial: NCT05417269
Drug: IMCY-0141
RxNorm normalized name: IMCY-0141
DrugBank: IMCY-0141 (DB17019)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The investigational medicinal product (IMP) consists in a small synthetic peptide (23 amino acids - IMCY-0141) combining a known human epitope of MOG flanked with a thioredox motif, presented in the form of a freeze-dried sterile powder and diluent for subcutaneous (SC) administration. The diluent includes the adjuvant aluminium hydroxide (alum) at a concentration of 900 μg/mL. Treatment will be injected within 4h of resuspension of the powder with the diluent.~Treatment will consist of 6 immunizations (separated by 14 days) of the IMP by SC injection in the upper arm, in the region of the triceps (lateral part of the arm, midway between the elbow and the shoulder). Half of the dose to be administered will be injected concomitantly in both arms.
Trial: NCT05417269
Drug: Dimethyl Fumarate
RxNorm normalized name: Dimethyl Fumarate
DrugBank: Dimethyl fumarate (DB08908)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dimethyl Fumarate (DMF) will be given orally, according to its SmPC for the whole duration of the study.~Dimethyl Fumarate (DMF) will be administered to patients randomized in the active control group during Phase II only.
Trial: NCT04048707
Drug: Angiotensin II
RxNorm normalized name: Angiotensin II
DrugBank: Angiotensin II (DB11842)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Intravenous
Trial: NCT04048707
Drug: Midodrine
RxNorm normalized name: Midodrine
DrugBank: Midodrine (DB00211)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pill
Trial: NCT04048707
Drug: Octreotide
RxNorm normalized name: Octreotide
DrugBank: Octreotide (DB00104)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Subcutaneous
Trial: NCT04048707
Drug: Albumin solution
RxNorm normalized name: darbepoetin alfa in albumin solution
DrugBank: Albumin human (DB00062)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous suspension
Trial: NCT06279104
Drug: immune checkpoint inhibitor based therapy
RxNorm normalized name: Anti-tim3 checkpoint inhibitor mbg453
DrugBank: Sabatolimab (DB16322)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: immune checkpoint inhibitor based therapy for relapsed/refractory ovarian clear cell carcinoma
Trial: NCT05950061
Drug: Sertraline
RxNorm normalized name: Sertraline
DrugBank: Sertraline (DB01104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sertraline (200 mg/day) capsule